Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL154812 | 0.78 | POLB (0.46) | POLBPIK3CDGAA | |
| SCHEMBL22304297 | 0.76 | PIK3CD (0.37) | POLBPIK3CDGAA | |
| SCHEMBL25443684 | 0.74 | PIK3CD (0.50) | POLBPIK3CDGAA | |
| SCHEMBL21789474 | 0.74 | POLB (0.33) | POLBPIK3CDGAA | |
| SCHEMBL1233264 | 0.74 | POLB (0.33) | POLBPIK3CDGAA | |
| SCHEMBL9911469 | 0.72 | KDM4C (0.42) | POLBPIK3CDGAA | |
| SCHEMBL11764211 | 0.72 | POLB (0.41) | POLBPIK3CD | |
| SCHEMBL10175141 | 0.70 | MLYCD (0.38) | POLBGAA | |
| SCHEMBL22305813 | 0.70 | PIK3CD (0.33) | POLBPIK3CD | |
| SCHEMBL3216320 | 0.70 | KMT2A (0.35) | POLBPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017477-B2 | Janus kinase inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170044111-A1 | JANUS KINASE INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044111-A1 | JANUS KINASE INHIBITORS AND USES THEREOF | JAK3, JAK1, JAK2 | POLB 1540/4885PIK3CD 472/4885GAA 1769/4885 |
| US-10017477-B2 | Janus kinase inhibitors and uses thereof | JAK3, JAK1, JAK2 | POLB 1540/4885PIK3CD 472/4885GAA 1769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.